Alaris Infusion Recall Issued Over Low Voltage Problem

A recall has been issued for Alaris infusion pumps after the manufacturer recognized that the pump may experience a loss of communication between the processor and the keyboard, which could result in an unexpected discontinuation of medication, posing serious adverse health consequences to users including death.  

The Alaris electronic infusion pump recall was announced by the U.S. Food and Drug Administration on June 17, which has categorized the action as a class I recall, meaning that the agency believes the problem has a high probability of causing serious injury or death.

According to the manufacturer, if the Alaris PC unit is held on 1.4 volts rather than 1.8 volts, it may cause a loss of communication between the PC Unit main processor and the keyboard processor. If a loss of communication occurs between the two processors than the pump may not administer the proper amount of fluid resulting in under treatment.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Infusion pumps are used for administering controlled amounts of medications or other fluids to patients intravenously, intra-arterially, through epidural, and other commonly acceptable methods of administration. The pumps can become extremely hazardous to users if there is a malfunction that disrupts the quantity of medication being administered which may lead to overdose or under treatment.

The Alaris infusion pump recall includes the 8015 model containing the 9.12 software version. These pumps were manufactured by CareFusion Corporation of San Diego, California and distributed from September 21, 2012 through May 17, 2013 nationwide.

In the event of a communication error the Alaris PC unit will display either a “SYSTEM ERROR” or “CHANNEL DISCONNECTED” error message on the screen and disallow the user to use the “PAUSE” or “SILENCE” keys. The FDA is warning users that during the loss of communication, if the “SYSTEM ON” key is pressed it will result in termination of all infusions and could lead to serious injury or death.

The FDA is advising users to either stop using the affected Alaris infusion pump or to adopt the following recommendations. Fully charge the units prior to use, keep the unit plugged in at all times, and store a back-up infusion pump at all times. Users may continue to use the affected infusion pumps unless a programming change in required.

CareFusion is attempting to reach out to all customers who may have the affected infusion pumps within 60 days to update and correct the voltage on the keyboard processor. Users should contact CareFusion at 1-888-812-3266 if the pump displays a “SYSTEM ERROR” or a CHANNELL DISCONNECTED” message.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Pfizer Agrees Brain Tumor Lawsuits Over Depo-Provera Should Be Centralized in MDL
Pfizer Agrees Brain Tumor Lawsuits Over Depo-Provera Should Be Centralized in MDL (Posted 3 days ago)

Birth control shot manufacturer supports the consolidation of Depo-Provera brain tumor lawsuits, but argues that the claims should be centralized in the Southern District of New York, where the company is headquartered.